Evidence map›Paper›PMID 42397586›Full record

ReviewInnere Medizin (Heidelberg, Germany)2026

[Progression inhibition in chronic kidney disease].

Julia Weinmann-Menke, Jan Galle

Abstract readEnglish AbstractReview
PubMed Publisher
In one paragraph

Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Julia Weinmann-MenkeKlinik für Nephrologie des Zentrums für Innere Medizin, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 162, 61920, Heidelberg, Deutschland. julia.weinmann-menke@med.uni-heidelberg.de.
Jan GalleKlinik für Nephrologie und Dialyseverfahren, Klinikum Lüdenscheid, Lüdenscheid, Deutschland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The KDIGO guidelines 2024 on evaluation and treatment of chronic kidney disease (CKD) represent a comprehensive update of the 2012 guidelines, incorporating evidence from over 937 references across 197 pages. The guidelines retain the established CGA classification system (cause, glomerular filtration rate, GFR category, albuminuria category) while introducing strengthened recommendations for prevention of CKD progression. Key advances include expanded indications for sodium-glucose transporter 2 (SGLT2) inhibitors regardless of diabetes status (grade 1A recommendation for eGFR ≥ 20 ml/min per 1.73 m

Indexed as

Renal Insufficiency, ChronicDiabetic NephropathiesDisease ProgressionEndothelin Receptor AntagonistsGlomerular Filtration RateGlucagon-Like Peptide-1 Receptor AgonistsHumansMineralocorticoid Receptor AntagonistsPractice Guidelines as TopicSodium-Glucose Transporter 2 InhibitorsEndothelin Receptor AntagonistsGlucagon-Like Peptide-1 Receptor AgonistsMineralocorticoid Receptor AntagonistsSodium-Glucose Transporter 2 InhibitorsAldosterone synthase inhibitorsCombination therapiesEndothelin receptor antagonistsMineralocorticoid receptor antagonistsSodium-glucose transporter 2 inhibitors

Identifiers

PMID42397586

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.